Key facts
- It has raised $18.9M; the latest was Accelerator/Incubator in Apr 2026.
- Notable investors include Endless Frontier Labs, Phoenix Court, Fresh.Fund, Nexus NeuroTech Ventures, SilverArc Capital Management — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Modulight Biotherapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Modulight Biotherapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Modulight Biotherapeutics
Developer of optogenetic therapy intended to treat neuronal overactivation disorders. The company's therapy harnesses endogenous cellular mechanisms to achieve synapse-level modulation with unprecedented spatiotemporal resolution, enabling medical professionals to transform the treatment of severe neurological conditions worldwide.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2022
- Employees
- 24
- Website
- modulight.bio/
- Ownership
- Privately Held (backing)
Modulight Biotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Modulight Biotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Modulight Biotherapeutics in its N-PORT filings yet. We sweep new filings monthly.